UPDATE ON MULTIDRUG-RESISTANT TUBERCULOSIS: CHALLENGES AND OPPORTUNITIES IN THE TREATMENT OF ADULT PATIENTS WORLDWIDE COMPARED TO PANAMA FROM 2004 –2023

Authors

  • Stav Birger Latina University of Panama, student of the Doctor of Medicine and Surgery program. Panama, Panama City.
  • Sapir Leibovitch Latina University of Panama, student of the Doctor of Medicine and Surgery program. Panama, Panama City.
  • Ana Sofia Moreno Latina University of Panama, student of the Doctor of Medicine and Surgery program. Panama, Panama City.
  • Hannah Olle Latina University of Panama, student of the Doctor of Medicine and Surgery program. Panama, Panama City.
  • Ana Laura Parra Latina University of Panama, student of the Doctor of Medicine and Surgery program. Panama, Panama City.
  • Anlly Añez Latina University of Panama, student of the Doctor of Medicine and Surgery program. Panama, Panama City.

Keywords:

Multidrug resistant tuberculosis (MDR-TB), Panama, Treatment strategies, comorbidities

Abstract

Multidrug-resistant tuberculosis (MDR-TB) presents global challenges. In this study, we compare the treatment of MDR-TB in adults worldwide and in Panama. Resistance can be primary (without previous treatment) or secondary (due to failed treatments). Global incidence is influenced by environmental factors, living conditions, lifestyle, medical history, and comorbidities such as diabetes and HIV. The treatment of MDR-TB aims to limit disease progression and transmission, emphasizing the importance of adherence. In Panama, the Ministry of Health (MINSA) employs standardized chemotherapy regimens but faces administrative challenges in reporting cases, affecting treatment coverage. Treatment costs are high, and quality-assured medications are expensive, posing a risk for resource-limited countries. Novel diagnostic and therapeutic approaches, such as the FAST protocol and other treatments, show promise in improving outcomes. Surgical resection can complement medical treatment in cases of multiple drug resistance. However, the adverse effects of medications and the need for prolonged treatment remain concerns, requiring comprehensive health system involvement in combating this international epidemiological problem.

References

Assefa, D.G., Bedru, A., Zeleke, E.D. et al.(2023). Efficacy and safety of different regimens in the treatment of patients with latent tuberculosis infection: a systematic review and network meta-analysis of randomized controlled trials. Arch Public Health 81, 82. https://doi.org/10.1186/s13690-023-01098-z

Bouzeyen, R., & Javid, B. (2022). Therapeutic Vaccines for Tuberculosis: An Overview. Retrieved from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC 9263712/

Carr W., Kurbatova E., Starks A., Goswami N., Allen L., Winston C. (2022). Interim guidance: 4-month rifapentine-moxifloxacin regimen for the treatment of drug-susceptible pulmonary tuberculosis - United State. MMWR Morb. Mortal Wkly Rep. 71, 285–289. doi: 10.15585/mmwr.mm7108a1

Gómez-Tangarife, V. J. et al. (2018). Resistencia a Medicamentos en Mycobacterium tuberculosis: contribución de mecanismos constitutivos y adquiridos. Revista de Salud Pública [online]. v. 20, n. 4, pp. 491-497. https://doi.org/10.15446/rsap.V20n4.50575

Jessany, G. J., & Mileica, J. (2018). Factores de riesgo asociados a multidrogorresistencia en pacientes con tuberculosis. 2011-2015. Panamá. Universidad de Panamá. Vicerrectoría de Investigación y Postgrado.

Liebenberg, D., Gordhan, B. G., & Kana, B. D. (2022). Drug resistant tuberculosis: Implications for transmission, diagnosis, and disease management. Frontiers in cellular and infection microbiology, 12, 943545. https://doi.org/10.3389/fcimb.2022.943545

Oh, C. E., & Menzies, D. (2022). Four months of rifampicin monotherapy for latent tuberculosis infection in children. Clinical and experimental pediatrics, 65(5), 214–221. https://doi.org/10.3345/cep.2021.01186

Organización Mundial de la Salúd (OMS). (2023). La respuesta a la tuberculosis se recupera de la pandemia pero es necesario acelerar las actividades para cumplir las nuevas metas. https://www.paho.org/es/noticias/7-11-2023-respuesta-tuberculosis-se-recupera-pandemia-pero-es-necesario-acelerar

Salari, N., Kanjoori, A.H., Hosseinian-Far, A. et al. (2023). Global prevalence of drug-resistant tuberculosis: a systematic review and meta- analysis. Infect Dis Poverty 12, 57. https://doi.org/10.1186/s40249-023-01107-x

Santana Vallejos, X. (2018). Factores de riesgo asociados al fracaso en la terapia antituberculosa, estrictamente supervisada en la región metropolitana de salud año 2014-2015. Universidad de Panamá. Vicerrectoría de Investigación y Postgrado. http://up- rid.up.ac.pa/1592/

Shuaib, Y. A., Utpatel, C., Kohl, T. A., Barilar, I., Diricks, M., Ashraf, N., Wieler, L. H., Kerubo, G., Mesfin, E. A., Diallo, A. B., Al-Hajoj, S., Ndung’u, P., Fitzgibbon, M. M., Vaziri, F., Sintchenko, V., Martinez, E., Viegas, S. O., Zhou, Y., Azmy, A., Merker, M. (2022). Origin and global expansion of mycobacterium tuberculosis complex lineage 3. MDPI. https://www.mdpi.com/2073-4425/13/6/990

Tobón, A., Paniagua, L., Henao, M., Arcila, V., Maya, J., Bedoya, F., & Muñoz, B. (2004). Cirugía en tuberculosis pulmonar multirresistente. Biomédica, 24(Suppl. 1), 65-72. http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S012041572004000500010&lng=en&tlng=es

Turner, R. E., Lawson, C., Garrido, L. A., Ibarra, Y., & Burgos, M. (2008). POLÍTICA PÚBLICA NACIONAL SOBRE EL VIH Y SIDA. Organización Panamericana de la Salud.https://www3.paho.org/pan/dmdocuments/Politica%20y%20legislacion%20sobre%20el%20VIH%20y%20sida.pdf

World Health Organization (2018). WHO Multidrug-Resistant Tuberculosis (MDR-TB), 2018 Update https://cdn.who.int/media/docs/default-source/documents/tuberculosis/multidrug-resistant-tuberculosis-mdr-tb88d59c05-8877-41db-850b 5afa6ad416de.pdf?sfvrsn=dfb1f2f1_1&download=true

World Health Organization (2020). WHO consolidated guidelines on tuberculosis, module 4: Treatment - drug-resistant tuberculosis treatment (Geneva: World Health Organization;)

Downloads

Published

2024-07-29

How to Cite

Birger, S., Leibovitch, S., Moreno, A. S., Olle, H., Parra, A. L., & Añez, A. (2024). UPDATE ON MULTIDRUG-RESISTANT TUBERCULOSIS: CHALLENGES AND OPPORTUNITIES IN THE TREATMENT OF ADULT PATIENTS WORLDWIDE COMPARED TO PANAMA FROM 2004 –2023. Scientific Behavior, 7(2), 9–33. Retrieved from http://revistas.ulatina.edu.pa/index.php/conductacientifica/article/view/367

Issue

Vol. 7 No. 2 (2024): Scientific Conduct, Journal of Health Sciences Research

Section

Articles

License

Copyright (c) 2024 Stav Birger, Sapir Leibovitch, Ana Sofia Moreno, Hannah Olle, Ana Laura Parra, Anlly Añez

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

El contenido de las publicaciones son responsabilidad absoluta de los autores y no de la Universidad ni de la revista Conducta Científica, que es editada por la Universidad Latina de Panamá.  La revista permite a los autores mantener el derecho de autor sobre los articulos y documentos publicados mediante el uso de la siguiente licencia.

Los artículos se publican con una licencia https://creativecommons.org/licenses/by-nc-sa/4.0/deed.es

Bajo los siguientes términos:

  • Atribución — Usted debe dar crédito de manera adecuada, brindar un enlace a la licencia, e indicar si se han realizado cambios. Puede hacerlo en cualquier forma razonable, pero no de forma tal que sugiera que usted o su uso tienen el apoyo de la licenciante.

  • NoComercial — Usted no puede hacer uso del material con propósitos comerciales.

  • CompartirIgual — Si remezcla, transforma o crea a partir del material, debe distribuir su contribución bajo la misma licencia del original.